This study investigated the effects of curcumin, the active polyphenol in turmeric, on iron overload, hepcidin level, and liver function in β-thalassemia major patients. This double-blind randomized controlled clinical trial was conducted on 68 β-thalassemia major patients. The subjects were randomly divided into 2 groups to receive either 500 mg curcumin capsules (total: 1,000 mg) twice daily or placebo for 12 weeks. (46.30 ± 10.85 vs. 50.99 ± 9.36 U/L, p = .009) in curcumin group in comparison with placebo group. There were no significant changes in hepcidin and other variables in any of the 2 groups. Curcumin administration alleviated iron burden and liver dysfunction by reducing NTBI, ALT, and AST levels in patients with β-thalassemia major.
1 | INTRODUCTION β-Thalassemia major is the most common congenital hemolytic anemia worldwide, which is characterized by reduced synthesis of hemoglobin (Hb) β-globin (Gardenghi et al., 2007) . Iron overload, the main complication of β-thalassemia major, results from an increased absorption of iron in the gastrointestinal tract and is greatly exacerbated by frequent transfusion therapy (Gardenghi et al., 2007) . The hepatic peptide hepcidin inhibits the entry of iron into the plasma via several mechanisms and regulates iron homeostasis in the body (Ganz & Nemeth, 2012) . In β-thalassemia, ineffective erythropoiesis causes a compensatory decrease in hepcidin expression and consequently results in increased intestinal iron absorption (Ganz & Nemeth, 2012; Camberlein, Zanninelli, Détivaud, et al., 2008) . When transferrin is oversaturated and there is insufficient amount of ferritin as the major iron storage protein for excess content of incoming iron, it accumulates as nontransferrin bound iron (NTBI) (Fibach & Rachmilewitz, 2010) . Therefore, iron chelation regimes are essential in preventing organ failure and decreasing mortality in these patients (Gardenghi et al., 2007) .
Deferoxamine is the most common iron chelator in clinical practice (Kwiatkowski, 2011) . Although effective, there are significant difficulties associated with its use such as parenteral administration (Rachmilewitz & Giardina, 2011) . Deferiprone and deferasirox, the oral iron chelators, are accompanied by better compliance of patients (Rachmilewitz & Giardina, 2011) . Nonetheless, a perfect oral iron chelator does not exist (Meerpohl et al., 2012; Weeraphan et al., 2013) .
Developing a safe and effective oral chelator as an alternative to deferoxamine or for use in combined therapy has been a significant aim in the management of β-thalassemia major (Fibach & Rachmilewitz, 2010 , Weeraphan et al., 2013 .
Curcumin (diferuloylmethane), the active polyphenol in turmeric, has been used for hundreds of years as a flavor, spice, and preservative especially in Asian countries (Kunnumakkara et al., 2017) . There is growing interest in the use of curcumin due to its significant therapeutic properties such as antioxidant, anti-inflammatory, and anticancer activities (Ak & Gülçin, 2008; Jiao et al., 2009; Milani, Basirnejad, Shahbazi, & Bolhassani, 2017; Nasseri et al., 2017) . Moreover, evidence from experimental models indicates that curcumin has iron binding capacity, induces iron removal, and alleviates liver damage (Chin, Huebbe, Frank, Rimbach, & Pallauf, 2014; Jiao et al., 2006; Lee et al., 2016) . Finding a natural iron chelator of plant origin that also acts as a hepcidin agonist can be useful in the management of excess iron in patients with β-thalassemia major (Nemeth, 2010) .
To the best of our knowledge, only one previous study exists that investigated the effects of curcumin in β-thalassemia patients using proteomic techniques (Weeraphan et al., 2013) . In the mentioned study, treatment with 500 mg curcuminoids for 12 months significantly reduced NTBI and plasma protein carbonyl and also alleviated oxidative stress by significantly decreasing the contents of malondialdehyde and reactive oxygen species. The glutathione level significantly increased, and activities of superoxide dismutase and glutathione peroxidase decreased, but the hematological parameters, serum ferritin level, function of liver and kidney, the lipid profiles, and uric acid content did not change. This study had some limitations.
It was not actually a randomized controlled clinical trial; the sample size was small; the control group consisted of healthy volunteers, and the dietary intakes of the patients that might influence the study outcomes were not assessed. Thus, the current study was conducted as the first randomized controlled clinical trial devoid of these limitations and with a reasonable sample size to evaluate the efficacy of curcumin on markers of iron overload, hepcidin level, and liver function in β-thalassemia major patients.
| MATERIALS AND METHODS

| Patients
Sixty-eight patients were recruited in this double-blind randomized controlled clinical trial from Amirkola Thalassemia Center in Babol, Mazandaran, Northern Iran, which has the highest prevalence of β-thalassemia in the country. Male and female patients with β-thalassemia major between 18 and 40 years old were eligible for inclusion in the trial if they were on stable medication with deferoxamine and regular transfusion program to keep the Hb level above the 9.5 mg/dl. The study exclusion criteria included changes in drug regimen during the study, taking any nutritional supplements within 3 months before the study or during the intervention period, having a history of hepatitis B, C, and HIV infection, pregnancy, and lactation. The sample size was determined on the basis of a primary outcome of a change in ferritin, according to Moayedi et al. (Moayedi et al., 2013) . By aiming for a confidence level of 95% and 80% power, Pocock formula was used to determine that at least 28 patients per group would be required to give an adequate sample size. To allow a dropout rate of 20%, the sample size was increased to 34 in each group.
| Ethical consideration
The study protocol was approved by the Ethics Committee of National 
| Experimental design
The patients were randomly allocated in two groups using a randomized block design via the random allocation software, with subjects matched in each block by sex and age. A general questionnaire including demographic characteristics and a history of treatment, transfusion, and chelation therapy was completed for each subject through comprehensive interviews. After overnight fasting, 5 ml venous blood samples were obtained from each patient just before the scheduled blood transfusion for measurement of the primary outcomes of the study including Hb, transferrin saturation (Ts), total iron binding capacity (TIBC), ferritin, NTBI, hepcidin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Hb was measured immediately after sampling. Then, serum was separated by centrifugation and stored in microtubes at −70°C until analysis. Curcumin have been approved by Food and Drug Administration as a safe herbal compound, in a way that there were no serious adverse effects of large dose of curcumin administration (up to 12 g/day) in clinical trials (Hewlings & Kalman, 2017; Gupta, Patchva, & Aggarwal, 2013) . Given that our study was among the first in patients with β-thalassemia major, reference was made to prior research conducted in other diseases including Type 2 diabetes (Usharani, Mateen, Naidu, Raju, & Chandra, 2008) , metabolic syndrome (Panahi, Khalili, Hosseini, Abbasinazari, & Sahebkar, 2014) , acute coronary syndrome (Alwi et al., 2008) , and prediabetic subjects (Thota, Acharya, Abbott, & Garg, 2016) , and a moderate dose of curcumin (1,000 mg) was considered for the present trial. Subjects in curcumin group (N = 34) received two 500 mg curcumin capsules (Aburaihan Pharmaceutical Company, Tehran, Iran) daily for 12 weeks. β-Thalassemia major patients in placebo group (N = 34) administered two placebo capsules, which were filled with corn starch daily (Aburaihan Pharmaceutical Company, Tehran, Iran) for the same period. Placebo and curcumin capsules were similar in size, weight, and color. The patients and researchers were blinded to the study treatment. The allocation was performed by one of the staff who was not involved clinically in the study, and the capsules were distributed among the subjects based on the allocation code after randomization. The compliance of the participants with the study procedure was monitored via phone interviews, twice a month, and also at each monthly visit through a capsule count. They received a new supply of capsules in monthly referral to thalassemia center for blood transfusion. Regular deferoxamine therapy continued during the study for all participants. The patients who needed additional medication or changes in defroxamine dose were excluded from the trial. The patients were advised to maintain their habitual diet and physical activity levels during the study. There were no cointerventions in the present study. Blood sampling required for measurement of biochemical parameters was repeated at the end of the follow-up period for both groups.
| Anthropometric and dietary assessment
Anthropometric assessment was performed at the beginning and the end of the trial for all patients. Body weight was measured in lightweight clothing and without shoes to the nearest 0.5 kg, using a scale (Seca, Germany). Height was measured by a mounted tape without shoes to the nearest 0.1 cm accuracy using a stadiometer (Seca, Germany). Body mass index (BMI) was calculated as the weight in kilogram divided by the square of the height in meters. Daily dietary intakes of subjects were assessed by 24-hr recall method for 3 days (two weekdays and one weekend) at the beginning and the end of study. Food intake was assessed to control the effects of dietary factors especially intake of iron and components, which are capable of interacting with iron absorption on study outcomes. Data on the amounts of all foods consumed were entered into Nutritionist 4 software (First Databank Inc., Hearst Corp., San Bruno, CA). Then the energy, macronutrient, and micronutrient contents of all foods were calculated with the software and the corresponding 3-day average of dietary intakes obtained.
| Biochemical measurements
Hb was measured using automated blood cell counter (Sysmex, Kobe, Japan). TIBC was determined by a colorimetric procedure and Pars Azmun Kit (Karaj, Iran). Ts was calculated as the ratio of serum iron (μg/dl)/TIBC (μg/dl) × 100. Levels of NTBI were determined by flame atomic absorption spectroscopy method as described previously (Dresow, Petersen, Fischer, & Nielsen, 2008) and using Shimadzu spectrometer (Kyoto, Japan). Serum ferritin and hepcidin levels were assessed by enzyme-linked immunosorbent assay method, using Monobind kit (Lake Forest, CA, USA) and ZellBio kit (Germany), respectively. Serum ALT and AST were measured by spectrophotometric technique via Pars Azmun kit (Karaj, Iran).
| Statistical analysis
Statistical analysis was performed using SPSS software (version 17; SPSS Inc., Chicago, IL). The normality of data distribution was determined using the one-sample Kolmogorov-Smirnov test. For serum hepcidin levels that did not follow normal distribution, analyses were conducted after log transformation. Mean values of dietary intakes, BMI, and biochemical measurements in two groups at baseline were compared using independent sample t test. Analysis of covariance was used to identify any differences in biochemical variables between two groups after trial, adjusting for baseline values and covariates (dietary intakes of iron and zinc as independent variables). Mean values of dietary intakes, BMI, and biochemical parameters before and after the trial were compared within groups using the paired t test.
The percentage of changes in variables after intervention was also determined: ([after values−before values]/before values) × 100. A p value less than .05 was considered to be statistically significant. The results are shown as mean ± standard deviation. Intention-to-treat analysis was not used in this study.
| RESULTS
Of the 68 patients, 61 participants (n = 31 in curcumin group and n = 30 in placebo group) completed the trial. Seven subjects were excluded from the study because of changes in chelation therapy, capsule discontinuation, and refusal of blood sampling due to some personal reasons. Figure 1 presents the diagram of the study design.
Curcumin was generally well tolerated, and there were no observed untoward side effects related to curcumin consumption during the study. Only two patients reported transient gastrointestinal discomfort such as nausea and abdominal pain at the beginning of the study, which spontaneously disappeared after 2 weeks. Capsule count showed that adherence to study protocol was acceptable in patients who completed the study, with more than 90% of the prescribed capsules being consumed by participants.
From Table 1 , no significant differences existed between groups in anthropometric measurements and clinical characteristics of patients at the onset of the study. Daily dietary intakes of participants at the baseline and end of 12-week intervention period are presented in Table 2 . No significant differences in energy and other dietary intakes were observed between the two groups at baseline, with the exception of the mean value of dietary zinc, which was significantly lower in curcumin group than placebo (p = .038). Total energy and nutrient intakes also did not change significantly in any of the groups during the study.
BMI and biochemical parameters of patients with β-thalassemia major are presented in Table 3 
| DISCUSSION
Preclinical and clinical evidences demonstrated that curcumin has a strong potential to protect against oxidative stress, inflammation, cancer, and metabolic and neurological diseases (Kunnumakkara et al., 2017 , Al-Karawi, Al Mamoori, & Tayyar, 2016 , Daily, Yang, & Park, 2016 , Sahebkar & Henrotin, 2016 , Nasseri et al., 2017 . In the present study, it was observed that curcumin supplementation significantly reduced serum NTBI, an index of free iron, in these patients.
There is limited evidence for the effects of curcumin on excess iron in β-thalassemia patients. In the only available report, proteomic method was applied to determine the protein profile and oxidative damage in the plasma of 10 β-thalassemia patients before and after curcumin treatment. Daily administration of 500 mg curcumin for 12 months in the mentioned research significantly reduced NTBI (Weeraphan et al., 2013) . Our findings are also in accordance with the results of an in vitro study by Srichairatanakool, Thephinlap, Phisalaphong, Porter, and Fucharoen (2007) Note. Data are presented as mean ± SD; BMI = body mass index.
4 months significantly reduced NTBI in iron-loaded mice (Thephinlap et al., 2011) .
NTBI comprises all forms of iron present in serum, which are not bound to transferrin and other iron binding proteins (Patel & Ramavataram, 2012) . Unbound iron in such patients is capable of generating highly reactive free radicals and is also known to cause tissue damage. Our results confirmed elevated levels of NTBI in patients with β-thalassemia major, while in normal healthy individuals, the value of NTBI does not exceed 1 μmol/L and is often unmeasurable by most of the methods (Patel & Ramavataram, 2012 -curcumin complex and participates in NTBI chelation (Srichairatanakool et al., 2007) . Curcumin, similar to some other low molecular weight flavonoids, might have a synergistic effect on iron chelating property of deferoxamine through an iron shuttle (Fibach & Rachmilewitz, 2010) . The iron shuttle hypothesis has been previously demonstrated for deferiprone, which is capable of penetrating cells and mobilizing iron from tissues into circulation where it binds to deferoxamine and is excreted in urine (Cao & Galanello, 2010) .
The peptide hormone hepcidin inhibits release of iron from macrophages, entrecotes, and hepatocytes into the plasma via degradation of a transmembrane iron exporter, ferroportin (Moayedi et al., 2013; Thephinlap et al., 2011) . It is suggested that globin chain impairment in β-thalassemia major causes ineffective erythropoiesis, anemia, and increased erythropoietin production, which results in enhanced erythroferrone production, an erythroid-derived hormone that reduces hepcidin synthesis in the liver (El Beshlawy, Alaraby, Abdel Kader, Ahmed, & Abdelrahman, 2012).
Based on our findings, strongly suppressed concentration of hepcidin was increased slightly by 12.3% after curcumin intervention, although these changes were not statistically significant.
There has been very little research that investigated the effects of natural or synthetic iron chelators on serum concentration of hepcidin in β-thalassemia major. Concentration of hepcidin tended to increase in the curcumin supplemented patients, which varied from the results of Jiao et al. (2009) . They showed that 6-month intervention with 2% curcumin in iron depleted mice that received 5 mg iron/kg diet, significantly reduced hepcidin level (Jiao et al., 2009) . Nevertheless, hepcidin level remained unchanged in mice that received iron at ≥12 mg/kg diet or those that received lower dose of curcumin (Jiao et al., 2009 ). In another experimental study, 6-month dietary supplementation with 0.2% curcumin in mice significantly suppressed the expression of liver hepcidin, but ferroportin, the target protein for hepcidin, did not change (Chin et al., 2014) . On the other hand, in iron over-loaded patients with low-risk myelodysplastic syndrome, .718
Data are presented as mean ± SD. a p value is reported based on the analysis of paired sample t test.
b p value is reported based on the analysis of independent sample t test.
3 months of iron chelation therapy with deferoxamine, the synthetic iron chelator, significantly increased serum hepcidin levels (Ghoti et al., 2011) . It should be noted that the expression of hepcidin as a key regulator of iron metabolism and hemostasis is dependent on body iron status (Fibach & Rachmilewitz, 2010) . The physiological conditions of participants in the above studies, including normal iron status (Chin et al., 2014) and subclinical iron deficiency (Jiao et al., 2009) were different from iron overload condition in our trial. As a result, contrary responses to curcumin are not unexpected. It is suggested that iron chelating factors are capable of stimulating hepcidin expression through alleviation of iron burden and erythropoietic activity (Ghoti et al., 2011) .
Based on our results, 12 weeks curcumin administration did not significantly affect Hb, Ts, TIBC, and ferritin in patients with β-thalassemia; nonetheless, a remarkable decrease was observed in ferritin levels (p = .059). Weeraphan et al. also demonstrated that daily intake of 500 mg curcumin for 12 months was unable to change Hb and ferritin in these patients (Weeraphan et al., 2013) . Although the present results did not agree with the findings of Chin et al. (2014) and Jiao et al. (2009) . These animal studies showed that dietary curcumin reduced Hb (Jiao et al., 2009) , Ts (Jiao et al., 2009) , and ferritin (Chin et al., 2014; Jiao et al., 2009) in normal (Chin et al., 2014) and iron depleted mice (Jiao et al., 2009 ). In another research, liver ferritin was decreased in mice after a 12-week dietary supplementation with 1.5% curcumin but not in the group fed 0.4% curcumin (Jiao et al., 2006 ). In the current study, when participants in curcumin group were stratified by baseline serum ferritin levels, effect of curcumin intervention was statistically significant in patients with serum ferritin levels >1,500 ng/ml (p = .046), suggesting that curcumin could significantly decrease ferritin levels in patients with severe iron overload.
It is likely that the controversy in the results obtained by mentioned studies originated from different clinical characteristics of the participants, curcumin doses, duration of the intervention, and research methodology. In addition, the study outcomes may be influenced by the supplement formulation. It is suggested that native curcumin has low bioavailability because of its hydrophobic nature, while some researchers have claimed that nanoparticles formulation improves curcumin bioavailability and therapeutic efficacy (Nemeth, 2010; García-Ni o & Pedraza-Chaverrí, 2014) .
Elevated serum levels of ALT and AST, clear markers of liver injury, were observed in the studied subjects. It was also discovered that curcumin decreased serum levels of ALT and AST. Weeraphan et al. did not find any significant changes in ALT and AST levels after curcumin administration in patients with β-thalassemia major (Weeraphan et al., 2013) . Despite that, recent studies in nonalcoholic fatty liver disease (Rahmani et al., 2016) , subjects with elevated ALT levels (Kim et al., 2013) and rats with liver damage (Lee et al., 2016) have supported our results. The most important mechanism underlying the liver protective property of curcumin is inhibition of hepatic oxidative stress and lipid peroxidation by reducing free iron (Lee Data are presented as mean ± SD. ALT = alanine aminotransferase; AST = aspartate transaminase; BMI = body mass index; Hb = hemoglobin; NTBI = nontransferrin bound iron; TIBC = total iron binding capacity; Ts = transferrin saturation. a MD (95% CI), p value is reported based on the analysis of paired sample t test.
b MD (95% CI), p value is reported based on the analysis of independent sample t test. c MD (95% CI), p value is reported based on the analysis of covariance. Rahmani et al., 2016) . The molecular targets of curcumin such as suppression of nuclear factor-kappa B (NF-kB), which is a cardinal regulator of inflammatory response and activation of the nuclear erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) pathway cannot be discarded to contribute to the beneficial effects of curcuminin on reducing iron toxicity in liver 
| CONCLUSION
In summary, curcumin administration had some beneficial effects on excess iron and liver function by reducing serum NTBI, ALT, and AST in patients with β-thalassemia major, though hepcidin level did not change. Other researches are required to provide more evidence to advise curcumin as a complementary treatment for ameliorating iron overload and related liver complications in these patients.
